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suOBJECTIVES The aims of this study were to characterize the association of high-sensitivity cardiac troponin I (hs-cTnI)
with heart failure (HF), to determine its predictive value beyond classical cardiovascular risk factors (CVRFs) and
N-terminal pro–B-type natriuretic peptide, and to derive a relevant cutoff for potential clinical application.
BACKGROUND HF is an important contributor to the overall burden of cardiovascular disease. Early identification of
individuals at risk could be beneficial for preventive therapies.
METHODS Based on the Biomarker for Cardiovascular Risk Assessment in Europe consortium, we analyzed individual-
level data from 4 prospective population-based cohort studies including 48,455 individuals. Participants with myocardial
infarction, HF, and stroke at baseline were excluded. We investigated the value of adding hs-cTnI to CVRFs and
N-terminal pro–B-type natriuretic peptide using Cox proportional hazards survival models and for prediction by
calculating C-statistics and Brier score.
RESULTS The median age of the study population was 51 years, and the median follow-up time for occurrence of HF
was 6.61 years. Cox regression models adjusted for age, sex, and CVRFs revealed a significant association of hs-cTnI with
incident HF (hazard ratio: 1.42 per log [ng/l] unit change [95% confidence interval: 1.31 to 1.53]). The best predictive
value was achieved in the model with CVRFs (base model) and both biomarkers (C-index ¼ 0.862; 95% confidence
interval: 0.841 to 0.882). Optimal hs-cTnI cutoff values of 2.6 ng/l for women and 4.2 ng/l for men were derived for
selecting individuals at risk.
CONCLUSIONS In this large dataset from the general population, hs-cTnI could show its independence for the
prognosis of HF. (J Am Coll Cardiol HF 2020;8:401–11) © 2020 The Authors. Published by Elsevier on behalf of
the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).N 2213-1779 https://doi.org/10.1016/j.jchf.2019.12.008
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402H eart failure (HF) is one of the lead-ing causes for morbidity and mor-tality in the Western population.
The crude prevalence of HF is projected to
increase by 25% over the next 20 years (1).
Among middle-aged adults, the 10-year risk
for new-onset HF is approximately 10% and
even higher in older individuals (2). HF is
diagnosed by its signs and symptoms, but
imaging parameters are used to group pa-
tients in different HF subtypes based on ejec-
tion fraction (EF). Nevertheless, morbidity
and mortality are similar for the different
types (3). Treatment options for patients
with reduced EF are improving, but in pa-
tients with only mildly reduced or preserved
EF, no established therapy is available. This
makes primary prevention of HF one of the
unmet goals in HF research.SEE PAGE 412A biomarker-driven diagnostic approach could
potentially allow early identification of individuals at
risk for developing HF. To date, established markers
for risk prediction of incident HF are limited and
seldom used in clinical practice.
N-terminal pro–B-type natriuretic peptide (NT-
proBNP) is widely applied in the diagnosis and prog-
nosis assessment of HF (4). A potential use in the
context of the prediction of incident HF has also been
demonstrated (5). Besides NT-proBNP, troponin is the
most established cardiac biomarker and is used as the
gold standard to detect myocardial injury (6,7). Novel
high-sensitivity cardiac troponin (hs-cTn) assays may
even allow application as a prognostic biomarker
because very low concentrations can be detected (8).
There is first evidence that even these low hs-cTne, Italy)–Programma Triennale di Ricerca, Decreto n.1588, and Ins
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received September 10, 2019; revised manuscript received Decemconcentrations show a graded and independent as-
sociation with incident HF (9–11). Also, Evans et al.
(12) showed the association in their study. However,
the pathophysiology as well as the prognostic impli-
cations of increased hs-cTn concentrations are not yet
completely understood. Besides, cutoff values have
not been uniformly defined and are always assay
specific.
To examine the association of high-sensitivity car-
diac troponin I (hs-cTnI) with HF in the general popu-
lation, we conducted an analysis of prospective cohort
studies within the BiomarCaRE (Biomarkers for Car-
diovascular Risk Assessment in Europe) consortium.
The aims of this study were to characterize the asso-
ciation of hs-cTnI with incident HF, to determine its
predictive value beyond classical cardiovascular risk
factors (CVRFs) and NT-proBNP, and to derive a rele-
vant cutoff for potential clinical application.
METHODS
STUDY OVERVIEW. The BiomarCaRE consortium is a
European Union–funded consortium including 31 in-
stitutions. BiomarCaRE aims to determine the value of
established and emerging biomarkers to improve risk
prediction of cardiovascular disease in Europe. Bio-
marCaRE relies on large-scale epidemiological cohorts
with long-term follow-up based on the population of
the MORGAM (MONICA Risk, Genetics, Archiving and
Monograph) project as well as several cardiovascular
disease cohorts and clinical trials. All epidemiological
and clinical phenotypes as well as disease outcomes
have been harmonized in a database (13).
STUDY COHORTS. Overall, the present analysis is
based on the data of 4 population-based cohort
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TABLE 1 Baseline Characteristics of the Study Population
All
(N ¼ 48,455)
DanMONICA
(n ¼ 7,315)
FINRISK
(n ¼ 7,702)
Moli-sani
(n ¼ 23,179)
Northern Sweden MONICA
(n ¼ 10,259)
HF follow-up time, yrs 6.61 (6.55–6.66) 23.8 (18.8–27.4) 13.8 (13.8–13.9) 4.3 (3.4–5.3) 12.8 (7.8–20.9)
Age at baseline examination, yrs 50.7 (41.0, 60.7) 49.9 (39.8, 60.0) 47.1 (36.3, 58.1) 53.9 (45.5, 63.4) 47.8 (36.9, 58.7)
Men 23,321 (48.1) 3,662 (50.1) 3,758 (48.8) 10,943 (47.2) 4,958 (48.3)
Female 25,134 (51.9) 3,653 (49.9) 3,944 (51.2) 12,236 (52.8) 5,301 (51.7)
Cardiovascular risk factors
Body mass index, kg/m2 26.5 (23.7, 29.7) 24.3 (22.1, 27.1) 26.0 (23.4, 28.9) 27.4 (24.7, 30.7) 26.2 (23.5, 29.5)
Diabetes 2,208 (4.6) 157 (2.1) 366 (4.8) 1,367 (5.9) 318 (3.1)
Daily smokers 11,679 (24.2) 3,265 (44.6) 1,683 (22.2) 4,834 (20.9) 1,897 (18.6)
Hypertension 21,203 (43.8) 1,668 (22.8) 3,332 (43.3) 12,746 (55.0) 3,457 (33.7)
Systolic blood pressure, mm Hg 132.0 (119.5, 147.5) 121.0 (111.0, 134.0) 133.0 (121.0, 147.0) 138.0 (125.5, 153.0) 126.0 (115.0, 141.0)
LDL cholesterol, mmol/l 3.3 (2.6, 4.0) 3.6 (3.0, 4.4) 2.7 (2.1, 3.3) 3.2 (2.7, 3.8) 3.5 (2.7, 4.4)
HDL cholesterol, mmol/l 1.4 (1.2, 1.7) 1.4 (1.2, 1.7) 1.4 (1.1, 1.6) 1.4 (1.2, 1.7) 1.3 (1.1, 1.6)
Triglycerides, mmol/l 1.2 (0.9, 1.7) 1.1 (0.8, 1.6) 1.2 (0.9, 1.7) 1.2 (0.9, 1.7) 1.2 (0.9, 1.8)
Total cholesterol, mmol/l 5.6 (4.9, 6.4) 5.7 (5.0, 6.5) 5.4 (4.8, 6.2) 5.5 (4.8, 6.2) 5.8 (5.0, 6.7)
Antihypertensive medication 8,699 (18.2) 444 (6.3) 844 (11.3) 6,271 (27.2) 1,140 (11.3)
Biomarkers
eGFR, ml/min/1.73 m2 96.5 (85.1, 106.5) 98.9 (86.7, 109.8) 90.5 (78.2, 101.8) 94.8 (84.6, 103.3) 104.0 (92.8, 114.0)
hs-cTnI, ng/l 2.3 (1.4, 3.6) 2.8 (1.7, 4.2) 3.0 (2.0, 4.6) 2.2 (1.4, 3.3) 1.7 (0.9, 2.9)
NT-proBNP, ng/l 46.2 (24.5, 84.4) – 44.7 (23.8, 80.8) 48.3 (25.8, 88.7) 42.0 (21.8, 78.5)
Outcome during follow-up
Heart failure 1,990 (4.1) 609 (8.3) 485 (6.3) 508 (2.2) 388 (3.8)
Overall mortality 4,648 (9.6) 2,293 (31.3) 764 (9.9) 459 (2.0) 1,132 (11.0)
Values are median (95% confidence interval), or median (25th, 75th percentile), or n (%). Baseline characteristics for individuals free of heart failure, myocardial infarction and stroke at baseline. Results are
shown for all studies combined. We classified subjects with systolic blood pressure over 140 mm Hg or diastolic blood pressure over 90 mmHg or taking antihypertensive medication as being hypertensive.
Diabetes was defined as diagnosed, documented or self-reported.
LDL ¼ low-density lipoprotein cholesterol; HDL ¼ high-density lipoprotein cholesterol; eGFR ¼ estimated glomerular filtration rate, CKD-EPI formula; hs-cTnI ¼ high-sensitivity cardiac troponin I;
NT-proBNP ¼ N-terminal prohormone of brain natriuretic peptide.
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403particular DanMONICA, FINRISK, Moli-sani, and
Northern Sweden MONICA, comprising 48,455 in-
dividuals with 1,990 events of incident HF. The initial
aim of the participating studies was to monitor risk
factor levels in the population, keeping in mind that
such health examination surveys would also create a
valuable baseline for cohort studies.
In DanMONICA, 7,315 individuals were enrolled
from 1982 to 1992 for examination with a median
follow-up time of 24.06 years. A total of 7,702 par-
ticipants from FINRISK were admitted in 1997 for
examination with a median follow-up time of 13.84
years. Northern Sweden enrolled 10,259 individuals
from 1986 to 2009 for examination with a median
follow-up time of 12.85 years. At last, Moli-sani
enrolled 23,179 individuals from 2005 to 2010 for ex-
amination with a median follow-up time of 4.3 years.
All individuals included in this study were free of
cardiovascular disease containing HF, myocardial
infarction (MI), and stroke. Each study cohort is based
on a well-defined population (Table 1). Cohort de-
scriptions are provided in the Supplemental
Appendix. All participating cohort studies were
approved by local ethics committees; individuals
provided written informed consent.DEFINITION OF THE ENDPOINT. Each study center
was asked to decide on the exact definition of HF for
their cohorts. When routine clinical and death cer-
tificate diagnoses are used, the relevant International
Classification of Diseases codes are usually as follows:
International Classification of Diseases-8th Revision,
427.0, 427.1, and 428; International Classification of
Diseases-9th Revision, 428; and International Classi-
fication of Diseases-10th Revision, I50 (HF), I11.0
(hypertensive heart disease with HF), I13.0 (hyper-
tensive heart and renal disease with HF), and I13.2
(hypertensive heart and renal disease with both HF
and renal failure), which were adjusted according to
local coding practices. In all cohorts, the follow-up for
HF was based on linkage with hospital stay and cause
of death registers and in FINRISK also with the na-
tional drug reimbursement register. The codes actu-
ally used, often based on national modifications of
International Classification of Diseases-Eighth Revi-
sion and International Classification of Diseases-9th
Revision, are specified in the MORGAM e-publica-
tion (14).
STATISTICAL METHODS. Missing data were handled
by available case analyses; only those without missing
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404values on the variables involved in that particular
analysis were used. Continuous variables are pre-
sented as median (25th and 75th percentile) and bi-
nary variables as absolute and relative frequencies.
Survival curves for HF were computed according to
the following pre-selected categories derived from
the continuous hs-cTnI: low, <1.9 ng/l whereas
1.9 ng/l was the reported limit of detection of the
Abbott assay; moderate, 1.9 #3.2 ng/l; and
high, >3.2 ng/l whereas 3.2 ng/l divides participants
with a hs-cTnI $1.9 ng/l into 2 equal-sized subgroups,
respectively (15).
To examine the association of hs-cTnI with HF,
sex- and cohort-stratified Cox proportional hazards
survival models with MI during follow-up as a time-
dependent covariate were used. The use of sex and
cohort as stratification variables adjusts the models
for sex and cohort by allowing for a different baseline
hazard function for each level combination of these 2
variables (16). Because individuals with MI at baseline
were excluded, at the beginning of the follow-up
time, the binary MI variable used in the Cox models
was coded as 0 for all individuals, and it stayed this
way until an individual experienced an MI. At that
time, the variable value was updated to 1.
For these analyses, the Cox models were addi-
tionally adjusted in the first model for classical
CVRFs, body mass index, systolic blood pressure,
diabetes, smoking status, antihypertensive medica-
tion, low-density lipoprotein (LDL) cholesterol, and
kidney function (estimated glomerular filtration rate
[eGFR]). These variables were used as time fixed
covariates because they were only available at base-
line. Age was used as the time scale in all models.
Body mass index, systolic blood pressure, LDL
cholesterol, and eGFR were used as continuous vari-
ables. The reference category for diabetes is the
absence of diabetes. The reference category for
smoking is nonsmoking. The reference category for
antihypertensive medication is the absence of anti-
hypertensive medication.
In the first model, we added hs-cTnI to CVRFs. In
the second model, we added hs-cTnI to CVRFs and
NT-proBNP. Additionally, in the third model, we
studied the association of NT-proBNP with HF after
adjustment for CVRFs.
The association of hs-cTnI with HF was studied
with the same setting of variables for continuous and
categoric versions of hs-cTnI. The categorization of
hs-cTnI is described earlier. The categoric variable of
NT-proBNP was derived from the continuous version
as well defined as low, <30.91 ng/l; moderate,
$30.91 to <68.26 ng/l; and high, $68.26 ng/l. For
these analyses, both biomarkers were log transformedand winsorized. Hs-cTnI and NT-proBNP values
above the 99.5th percentile (106.6 ng/l and
1,356.2 ng/l, respectively) were winsorized.
The proportional hazard assumption was examined
graphically and with formal tests using the methods
described by Grambsch and Therneau (17). No evi-
dence of violations of this assumption was observed.
Hazard ratios for continuous versions of hs-cTnI or
NT-proBNP were reported per log (ng/l) unit change.
To examine the prognostic value of hs-cTnI and
NT-proBNP, the C-index (18), the Brier score (19), and
calibration plots (20) were used beyond that from a
model including CVRFs (defined as the base model in
this analysis). Additionally, we used the Akaike in-
formation criterion (AIC) to estimate the relative
quality of our statistical models (21).
One aim of this work was the determination of a
clinically relevant cutoff value for hs-cTnI. This was
done using the method of Contal and O’Quigley (22).
This technique uses the log-rank test statistic in order
to estimate the cutoff value. The optimal cutoff was
chosen to give the maximum separation between the
groups below and above the cutoff. The equality of
survival curves defined by the optimal cutoff was
tested using the methods described in the afore-
mentioned reference.
A 2-sided p value <0.05 was considered statisti-
cally significant. All statistical analyses were con-
ducted with R statistical software version 3.5.1 (23).
Data collection and biomarker measurement as well
as additional statistical information are detailed in
the Supplemental Appendix.
STUDY OUTCOME. Of 51,190 individuals, prevalent
HF, MI, and stroke cases (n ¼ 2,735) were excluded
from all analyses. There are 118 individuals with fatal
MI and HF with tied event times. For these in-
dividuals, we assumed the event of HF to take place
1 day before death caused by MI. Under this
assumption, these individuals could be included into
the analysis. Additionally, there are 106 individuals
who experienced nonfatal MI and HF at the same
time. For these individuals, we assumed the event of
nonfatal MI to take place 1 day before HF. The follow-
up time of these 106 individuals ends at the time of
experiencing MI. Sensitivity analyses underlying the
reversed order of events for 106 individuals with tied
event times provided similar conclusions.
RESULTS
BASELINE CHARACTERISTICS. Baseline characteris-
tics for the overall study population and of each in-
dividual cohort are shown in Table 1. The median
follow-up time for incident HF (95% confidence
TABLE 2 Performance Measures With C-Statistics, Brier Score, and Akaike Information Criterion
C-Index
(95% CI)
C-Index Difference to
Base Model (95% CI)
p Value of
C-Index Brier Score
Akaike Information
Criterion
Base model (CVRFs) 0.843 (0.822–0.863) 0.01553 12,081
Base model þ hs-cTnI 0.848 (0.828–0.869) 0.005 (0.003–0.008) <0.001 0.01545 11,998
Base model þ NT-proBNP 0.861 (0.841–0.882) 0.018 (0.012–0.025) <0.001 0.01511 11,790
Base model þ NT-proBNP þ hs-cTnI 0.862 (0.841–0.882) 0.019 (0.013–0.026) <0.001 0.01509 11,774
CVRF variables were used to adjust the cause specific Cox models. Myocardial infarction was used as competing risk. If no biomarker was used in the model, these variables
define the “base model.” The base model includes body mass index, systolic blood pressure, smoker status, diabetes mellitus, antihypertensive medication, low-density
lipoprotein, and kidney function. Models are stratified for cohort and sex. Age was used as the time scale of the Cox models (so they are implicitly adjusted for age).
Five-yr event probabilities were used to compute C-indices, the Brier score, and the Akaike information criterion. The p value of C-index is shown against the base model.
CI ¼ confidence interval; CVRF ¼ cardiovascular risk factor.
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405interval [CI]) was 6.61 (6.55 to 6.66) years. A total of
1,990 (4.1%) participants developed HF, and 1,965
(4.1%) experienced MI. The overall mortality was
9.6% (n ¼ 4,648). In the subgroup of individuals with
incident HF, MI and overall mortality were consider-
ably increased after the diagnosis of HF (MI ¼ 29.4%,
overall mortality ¼ 45.4%). The median age was 50.7
years; 51.9% (n ¼ 25,134) were women, and 48.1%
were men (n ¼ 23,321). The incident HF subgroup was
older with a median age of 61.2 years and was
composed of more male individuals (57.2%). The
median body mass index was 26.5 kg/m2; 43.8% were
hypertensive, 4.6% were diagnosed with diabetes,
and 24.2% were current smokers. The median LDL,
high-density lipoprotein, and total cholesterol values
were 3.3, 1.4, and 5.6 mmol/l, respectively. In the
subgroup developing HF, all CVRFs including body
mass index, systolic blood pressure, diabetes, smok-
ing status, and blood lipids were more frequent
(Supplemental Table 1). Missing information for in-
dividuals free of HF, MI, and stroke at baseline is
shown in Supplemental Table 2.
DISTRIBUTION OF BIOMARKERS. A total of 46,065
measurements of hs-cTnI and 41,140 measurements
of NT-proBNP were available. The distributions of
these 2 biomarkers are skewed to the right.
The median concentrations of hs-cTnI and NT-
proBNP were 2.3 ng/l and 46.2 ng/l, respectively
(Table 2). The distribution of hs-cTnI with cutoff
values for women and men and the reference value
are shown in Figure 1. In the subgroup developing HF,
baseline hs-cTnI was 4.0 ng/l, and NT-proBNP was
102.5 ng/l (Supplemental Table 1).
hs-cTnI AND ASSOCIATION WITH HF. As illustrated
in the unadjusted Kaplan-Meier survival analyses
across the categories of hs-cTnI levels, the probability
of HF rose with increasing hs-cTnI levels for women
and men (Figure 2).
Hazard ratios (HRs) for continuous hs-cTnI after
the addition to model 1 consisting of CVRF variableswere 1.42 (95% CI: 1.31 to 1.53; p < 0.001) and 1.19
(95% CI: 1.09 to 1.30; p < 0.001) after the addition to
model 2 with CVRFs and NT-proBNP.
Figure 3 displays adjusted (model 2) HRs of HF for
the categories of hs-cTnI and NT-proBNP using the
lowest categories as reference. We observed the
highest association for HF among those individuals
with hs-cTnI levels above 3.2 ng/l with HR of 1.63
(95% CI: 1.32 to 2.03; p < 0.001) and among those with
NT-proBNP levels above 68.26 ng/l with HR of 2.48
(95% CI: 2.02 to 3.03; p < 0.001). Cox proportional
hazard ratios for traditional cardiovascular risk fac-
tors is shown in Supplemental Table 3. Results from
combining the hs-cTnI and NT-proBNP categories and
showing event rates of new-onset HF are presented in
Supplemental Table 4.
hs-cTnI AND PREDICTION OF HF. The addition of
hs-cTnI to the base model for the prediction of HF
(C-index ¼ 0.848; 95% CI: 0.828 to 0.869; Brier
score ¼ 0.01553) led to an increment in the C-index of
0.005 (95% CI: 0.003 to 0.008; p < 0.001). The addi-
tion of hs-cTnI and NT-proBNP to the base model
yielded a C-index difference of 0.019 (95% CI: 0.013 to
0.026; p < 0.001) (Table 1). Further results of Brier
score are also given in Tables 1 and 3, indicating the
best results when adding both hs-cTnI and NT-
proBNP to the base model. Additionally, when hs-
cTnI was added to the base model, the AIC dis-
played a reduction from 12,081 (base model alone) to
11,998. The best predictive value with an AIC of 11,774
was found in the group with the base model, NT-
proBNP and hs-cTnI (Table 1). The calibration plot is
shown in Supplemental Figure 1.
CUTOFF VALUES OF hs-cTnI FOR
POTENTIAL PREVENTIVE THERAPIES
After the application of the method used by Contal
and O’Quigley (22), we calculated the cutoff value of
hs-cTnI. To take into account possible sex-specific
differences in hs-cTnI, we calculated 2 sex-specific
FIGURE 1 Distribution of hs-cTnI
The density (y-axis) of high-sensitivity cardiac troponin I (hs-cTnI levels) (x-axis) in the entire study population including 48,455 measure-
ments. Dashed lines correspond to the cutoff value for women (red), the cutoff value for men (blue), and the 99th percentile of hs-cTnI in
the healthy population (black).
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406cutoff values: 2.6 ng/l for women and 4.2 ng/l for
men. Figure 4 shows the Kaplan-Meier curves for
incident HF for 2 hs-cTnI categories divided by the
cutoff values. In the follow-up time, participants in
the category with hs-cTnI $2.6 (4.2) ng/l at baseline
showed a significantly higher risk for incident HF
compared with individuals with hs-cTnI under the
cutoff values.
DISCUSSION
The main findings of this study based on harmonized
data from large population-based cohorts are the
following:
1. The 10-year event rate of HFwith hs-cTnI ($3.2 ng/l)
and NT-proBNP ($68.26 ng/l) was at 13.2%;
2. hs-cTnI levels were independently associated with
incident HF;
3. The addition of hs-cTnI to a prognostic model
consisting of CVRFs improved prediction of inci-
dent HF;
4. The best prediction value for incident HF was
achieved by the combination of hs-cTnI and NT-
proBNP into 1 model; and5. Optimal hs-cTnI cutoff values of 2.6 ng/l for
women and 4.2 ng/l for men were derived to select
individuals at high risk (Central Illustration).
In the setting of pre-existing HF, scoring systems
like the Meta-analysis Global Group in Chronic
Heart Failure score (24) or the Seattle Heart Failure
Model (10) have been developed to predict survival. A
recent attempt to improve risk prediction by adding
NT-proBNP has shown promising results (25). The
addition of hs-cTnI to the established scoring systems
may further improve prediction of HF and may allow
tailored strategy for preventive therapies.
In this large population-based study, we focused
on individuals with no prior history of HF to assess
risk factors for possible prediction of incident HF. The
rate of incident HF was about 4.1% in this population,
and the median time to new-onset HF was 6.6 years.
As expected, classical CVRFs could identify partici-
pants at risk to develop HF (Figure 3). Importantly, we
show that hs-cTnI is associated with an increased
incidence of HF in this large dataset and improved
diagnostics on top of CVRFs. This is in agreement
with earlier and smaller publications reporting an
FIGURE 2 Kaplan–Meier Curves According to Categories of hs-cTnI for the Endpoint HF
Survival curves divided in the categories hs-cTnI low: <1.9 ng/l, hs-cTnI moderate $1.9 ng/l to <3.2 ng/l, hs-cTnI high $3.2 ng/l. HF ¼ heart
failure; hs-cTnI ¼ high-sensitivity cardiac troponin I.
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(9,26). Recently, Myhre et al. (27) showed an associ-
ation of troponin T and diastolic function in a cohort
of older adults.
Levels of hs-cTnI were low (Figure 2) as expected
when compared with patients with acute MI. Never-
theless, also slight increases of hs-cTn have been
shown to be important for risk predication in the
general population (9) and are associated with a poor
outcome. In our study, hs-cTnI concentrations of
2.6 ng/l for women and 4.2 ng/l for men predicted
incident HF. Currently, uncertainty remains about
the pathophysiology behind the hs-cTnI elevation.
Seliger et al. (28) showed that hs-cTnT levels are
associated with replacement fibrosis and progressive
changes in left ventricular structure in cardiovascular
disease–free adults using cardiac magnetic resonance.
In this study, we excluded individuals with prevalent
HF, MI, and stroke, which could have been respon-
sible for a subtle increase of troponin. However, the
long median time of more than 6 years until diagnosis
of incident HF implies that most of those individuals
were at good health at the time of inclusion and noclinical HF was present. The idea of troponin release
in the nonacute setting is also discussed by the fourth
definition of MI (29) with the inclusion of acute and
chronic myocardial injury. Similar mechanisms might
be responsible for the results in this study. Irre-
spective of the exact cause of troponin release, these
patients would possibly benefit from therapeutic
intervention. Our results suggest that hs-cTnI may
help to identify those individuals.
The association between NT-proBNP and the inci-
dence of HF is already established. In a randomized
controlled trial, Huelsmann et al. (30) demonstrated
the possibility of prevention of HF in persons with
elevated NT-proBNP measurement. In this trial, in-
dividuals with elevated NT-proBNP underwent tar-
geted prevention, resulting in a lower incidence of HF
compared with the control groups. In accordance, the
addition of NT-proBNP to a model containing classical
CVRFs in our analyses improved risk prediction of
HF. Nevertheless, similar to hs-cTnI, the detected
values were low and could also be the result of sub-
clinical myocardial injury causing this elevation.
Furthermore, soluble suppression of tumorigenesis 2
FIGURE 3 Hazard Ratios for Incident HF According to Categories of NT-proBNP and hs-cTnI
A total of 48,455 individuals were admitted from 1982 to 2010 for examination. The 95% confidence interval of the median follow-up is 6.61
(6.55 to 6.66). Cox regression analysis for the endpoint HF after adjustment for cardiovascular risk factors (body mass index, systolic blood
pressure, diabetes, smoking status, antihypertensive medication, low-density lipoprotein), kidney function (estimated glomerular filtration
rate), and N-terminal pro–B-type natriuretic peptide (NT-proBNP) (in this analysis designed as model 2). The reference category for NT-
proBNP was <30.91 ng/l. The reference category for hs-cTnI was <1.9 ng/l. Hazard ratios are reported per log (ng/l) unit change of hs-cTnI
or NT-proBNP. Black horizontal lines map 95% confidence intervals. Abbreviations as in Figure 2.
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However, soluble suppression of tumorigenesis 2
measurement was not available in most of the cohorts
and thus could not be included in our analysis.
Importantly, even when hs-cTnI was added to
CVRFs and NT-proBNP, there was an improvement of
prediction, albeit this was modest. Furthermore, this
might be important for understanding the patho-
physiology of the development of HF because next to
stress-induced elevation explained by NT-proBNP,TABLE 3 Novel Findings: What Is New?
hs-cTnI levels were independently associated with incident heart
failure (HF) with a hazard ratio of 1.42 in 48,455 individuals from
the general population.
The addition of hs-cTnI to a prognostic model consisting of
cardiovascular risk factors improved prediction of incident HF
(C-index 0.848 vs. 0.843).
The best prediction value for incident HF was achieved by the
combination of hs-cTnI and NT-proBNP with classical risk factors
(C-index ¼ 0.862).
10-yr event rates of HF differed relevantly between the lowest and
highest hs-cTnI and NT-proBNP categories (0.6% vs. 13.2%).other mechanisms causing myocardial injury seem
to play an important cause at this disease stage
already.
High cardiac troponin levels were associated with
future major adverse events including all-cause
mortality, MI, readmission for HF, and stroke in
other papers (9). Consequently, considering the
high prevalence in the general population, devel-
oping reasonable therapeutic strategies for patients
with elevated hs-cTnI levels in ambulatory primary
care could be very important. Therefore, the hs-
cTnI cutoff values of 2.6 ng/l for women and
4.2 ng/l for men beyond the CVRFs and NT-proBNP
derived in this study may serve as a basis for
future studies evaluating respective primary pre-
ventive strategies.
STUDY STRENGTHS AND LIMITATIONS. An impor-
tant strength of our study is the considerable size of
the dataset with harmonized data from well-defined
European population cohorts with 48,455 partici-
pants examining explicitly hs-cTnI as a risk marker
for HF. Several limitations have to be taken into
FIGURE 4 Kaplan–Meier Curves for Incident HF Based on the Calculated Cut-Off Value of hs-cTnI
(A) Survival curves based on cut-off value for women hs-cTnI <2.6 ng/l and $2.6 ng/l. (B) Survival curves based on cut-off value for men
hs-cTnI <4.2 ng/l and $4.2 ng/l. Abbreviations as in Figure 2.
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409account. One of the major limitations is that we
cannot provide information on HF subtypes (HF with
preserved and reduced ejection fraction) because
these were not consistently collected in the included
cohorts. Moreover, whether subclinical HF might
have been present at enrollment cannot safely be
ruled out in this population study. Another limitationis data on valvular heart disease, a possible risk factor
for HF, are not available in our cohorts.
CONCLUSIONS
In this large dataset of population cohort, hs-cTnI as
a biomarker could independently predict incident
CENTRAL ILLUSTRATION Predictive Value of hs-TnI for HF in the General Population
Classical risk factors
• Body mass index
• Systolic blood pressure
• Smoking
• Diabetes mellitus
• Low-density lipoprotein
• Kidney function
General population Heart failure
LOW RISK
HIGH RISK
hs-cTnl ≥2.6 ng/L
hs-cT
nl <2
.6 ng
/L
hs-
cTn
l <4
.2 n
g/L
hs-cTnl ≥4.2 ng/L
Predictive value (C-index)
with classical risk factors
alone: 0.843
Predictive value (C-index)
with classical risk factors and
hs-cTnl: 0.848
high-sensitivity
cardiac
troponin I
Yan, I. et al. J Am Coll Cardiol HF. 2020;8(5):401–11.
In this large dataset of healthy individuals, high-sensitivity cardiac troponin I (hs-cTnI) as a biomarker could show its independence for the prognosis of heart failure
and predictive value in addition to classical risk factors. An optimal high-sensitivity cardiac troponin I (hs-cTnI) cutoff value of 2.6 ng/l for women and 4.2 ng/l for men
was derived for selecting individuals who might benefit most from preventive strategies.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Elevation of serum hs-cTnI is associated with incident
HF. hs-cTnI showed a marginal predictive value for
HF.
TRANSLATIONAL OUTLOOK: Cutoff values of
2.6 ng/l for women and 4.2 ng/l for men were
established. Further studies are needed to determine
whether individuals with hs-cTnI > 2.6 ng/l/4.2 ng/l
might benefit from specific preventive therapy.
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410HF. The best prediction value for HF was achieved
after hs-cTnI was combined with NT-proBNP. The
usage of both biomarkers for the diagnosis of HF
could be essential for future clinical decision
making.
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